Τόμος 31 (2017) – Τεύχος 2 –Άρθρο 7 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 31 (2017) – Issue 2 – Article 7 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title

The Use of Cannabis and Cannabinoids for Medical Purposes
Συγγραφέας – Author

Sidiropoulou K.1, Mamalis S.1, Passos ID.2, Pliakou E.3, Mironidou- Tzouveleki M.1

1A’ Laboratory of Pharmacology, Faculty of Medicine, School of Health Sciences, Aristo- tle University of Thessaloniki, Greece.
2MD, PhD Candidate, A’ Laboratory of Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Greece.

3MD, MSc, PhD Candidate, B’ Laboratory of Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Greece.
Παραπομπή – Citation

Sidiropoulou K., Mamalis S., Passos ID., Pliakou E., Mironidou- Tzouveleki M. The Use of Cannabis and Cannabinoids for Medical Purposes. Review Clin. Pharmacol. Pharmacokinet. 2017, 31, 2, 120-129
Ημερομηνία Δημοσιευσης – Publication Date
2017
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords

Cannabinoids, cancer, CINV, Δ9-tetrahydrocannabinole (THC), cachexia, glaucoma
Λοιποί Όροι – Other Terms

Study
Περίληψη – Summary

The use of cannabis for its medicinal properties has been presented for centuries and has been increasing in recent years. Cannabinoids are the primary active components of cannabis and they can be divided into two groups: the ‘natural’ cannabinoids, such as Δ9-tetrahydrocannabinole (THC) and cannabidiol and the ‘synthetic’ cannabinoids, such as dronabinol, nabilone and nabiximols.

The aim of this study is to review the existing literature regarding the medical uses of cannabis and canna- binoids on a clinical level, as well as on a preclinical research level. Cannabinoids are more effective for the relief of nausea and vomiting than other medications like phenothiazines and antihistaminic drugs, as well as for certain types of chronic pain and weight loss in pa- tients with acquired immune deficiency syndrome (AIDS). Cannabinoids have also been studied for their anticancer effects, some of which are inhibition of tumor angiogenesis, decrease of cancer cell migration and temporary relief of symptoms. Nevertheless, no firm conclusions are yet possible, due to the small number of clinical trials in humans. Currently, the use of nabiximols for the treatment of pain and spasticity in multiple sclerosis is being researched in clinical trials.
Αναφορές – References

1. Aggarwal SK., Carter GT., Sullivan MD., ZumBrunnen C., Morrill R., Mayer JD Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 5:153-168 (2009)

2. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann. Intern. Med. 135:594–600 (2001)
3. Devinsky O., Cilio MR., Cross H., Fernandez-Ruiz J., French J., Hill C., Katz R., Di Marzo V., Jutras-Aswad D., Notcutt WG., Martinez-Orgado J., Robson PJ., Rohrback BG., Thiele E., Whalley B., Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 55:791– 802 (2014)

4. Kalant OJ. Report of the Indian Hemp Drugs Commis- sion, 1893–94: A critical review. Int J Addict. 7:77–96 (1972)
5.Bowles DW., O’Bryant CL., Camidge DR., Jimeno A. The intersection between cannabis and cancer in the United States.Crit Rev Oncol Hematol. 83:1-10 (2012)

6. Kramer J. Medical Marijuana for Cancer. CA Cancer J Clin. 65:109-122 (2015)
7. Borgelt LM., Franson KL., Nussbaum AM., Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 33:195-209 (2013)

8. Mechoulam R.,Parker L.A.,andGallilyR. Cannabidiol:anoverview of some pharmacological aspects. J.Clin.Pharmacol. 42:11–19 (2002)
9. Grotenhermen F., Müller-Vahl K. The therapeutic poten- tial of cannabis and cannabinoids. Dtsch Arztebl Int. 109: 495–501 (2012)

10. Brenneisen R. Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: Elsohly M, ed. Marijuana and the Cannabinoids. Totowa, NJ:Human Press, pp 17-51(2007)
11. Matsuda LA., Lolait SJ., Brownstein MJ., Young AC., Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:561–564 (1990)
12. Herkenham M., Lynn AB., Little MD., Johnson MR., Melvin LS., de Costa BR., Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 87:1932–1936 (1990)
13. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord 4:507–530 (2005)
14. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163:1344-1364 (2011)
15. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacothera- py. Pharmacol Rev. 58:389–462 (2006)
16. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N-N- ,diallyltyrosine-Aib-phenylalanine-leucine, ICL 174,864 ornaloxone in mice. J Pharmacol Exp Ther. 265:633–640 (1993)

17. Grotenhermen F. Pharmacokinetics and pharmacody- namics of cannabinoids. Clin Pharmacokinet. 42: 327–360 (2003)

18. Campos AC., Moreira FA., Gomes FV., Del Bel EA., Guimarães FS. Multiple mechanisms involved in the large- spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 367:3364– 3378 (2012)

19. Kathmann M., Flau K., Redmer A., Tränkle C., Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta- opioid receptors. Naunyn Schmiedebergs Arch Pharmacol .372:354-361 (2006)

20. Tsang CC., Giudice MG. Nabilone for the Management of Pain. Pharmacotherapy. 36:273-286 (2016)
21. Karschner EL., Darwin WD., Goodwin RS., Wright S., Huestis MA. Plasma cannabinoid pharmacokinetics follow- ing controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 57:66-75 (2011)

22. Meda Pharmaceuticals Inc. Cesamet [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc; 2011. cesamet.com/ pdf/Cesamet_PI_50_count.pdf. Accessed May 14 2014

23. Verrotti A., Castagnino M., Maccarrone M., Fezza F. Plant-Derived and Endogenous Cannabinoids in Epilepsy. Clin Drug Investig. 36:331-340 (2016)

35. Green K. Marijuana effects on intraocular pres- sure. Drance SM. Neufeld AH eds.Glaucoma Applied Pharmacology in Medical Treatment New York. NY Grune & Stratton Inc, pp 507-526 (1984)

36. Merritt JC., Crawford WJ., Alexander PC., Anduze AL., Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 87:222- 228(1980)
37. Green K. Marijuana smoking vs cannabinoids for glau- coma therapy. Arch Ophthalmol. 116:1433-1437 (1998)
38. Green K. Marihuana and the eye: a review. J Toxicol Cutan Ocul Toxicol. 1:13- 32 (1982)
39. Green K., McDonald TF. Ocular toxicology of marijua- na: an update. J Toxicol Cutan Ocul Toxicol. 6:309- 334 (1987)
40. Nucci C., Bari M., Spanò A., Corasaniti M., Bagetta G., Maccarrone M., et al Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 173:451-464 (2008)
41. Tomida I., Pertwee RG., Azuara-Blanco A. Canna- binoids and glaucoma. Br J Ophthalmol. 88:708-713 (2004)

42. Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed. 6 Suppl 3:21-22 (1999)
43. Reuter SE., Martin JH. Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clin Pharmacokinet. 2055:807-812 (2016)
44. Foltin RW., Fischman MW., Byrne MF. Effects of smoked marijuana on food intake and body weight of hu- mans living in a residential laboratory. Appetite. 11:1-14 (1988)

45. Beal JE., Olson R., Laubenstein L., Morales JO., Bellman P., Yangco B., Lefkowitz L., Plasse TF., Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 10:89-97 (1995)
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Bookmark the permalink.

Comments are closed.